Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron degenerative disease. TDP-43 (TAR DNA-binding protein 43) and FUS (fused in sarcoma) are aggregation-prone RNA-binding proteins that in ALS can mis-localize to the cytoplasm of affected motor neuron cells, often forming cytoplasmic aggregates in the process. Such mis-localization and aggregation are implicated in ALS pathology, though the mechanisms of TDP-43 and FUS cytoplasmic toxicity remains unclear.
Introduction
ALS is an adult-onset neurodegenerative disease characterized by progressive motor neuron degeneration, muscle weakness and fatal paralysis due to respiratory failure, which typically occurs 3-5 years after diagnosis. ALS is mostly a sporadic disease, with <10% of cases exhibiting a hereditary component [1, 2] [3] . Many ALS-linked mutations affect proteins involved in RNA metabolism or protein clearance pathways [2] , though mechanistic understanding of disease pathology remains unclear, and no effective treatment for ALS currently exists.
In >97% of ALS patients, a classic motor neuron hallmark of disease is re-localization from the nucleus to the cytoplasm of the RNA binding protein TDP-43, which also often forms ubiquitinated cytoplasmic protein aggregates ("inclusion bodies") in motor-neuron cells. In approximately 1% of familial ALS patients lacking TDP-43 pathology, similar behavior is exhibited by FUS, another RNA binding protein [2] . Cytoplasmic mis-localization and aggregation of FUS is more commonly observed in another related neurodegenerative disease, Fronto-temporal lobar dementia (FTLD), where about 10% of patients exhibit FUS aggregates. The remaining 90% of FTLD patients exhibit either aggregates of TDP-43 (45%) or the microtubule-associated protein Tau (45%) [2] . and FUS possess similar domains including RNA recognition motifs (RRMs) glycine rich domains and/or prion-like domains, and have been proposed to affect multiple steps of mRNA metabolism [4] [5] . dementia (IBMPFD) [34, 35] . As with ALS, IBMPFD also commonly exhibits cytoplasmic TDP-43 aggregates in affected cells (e.g. muscle cells, frontal cortex neurons) [34, 35] . Additionally, neurodegenerative effects of VCP mutants in flies depends upon TDP-43 cytoplasmic aggregation [36] . Finally, disease-alleles of VCP lead to accumulation of cytoplasmic TDP-43 aggregates in human cells [32] and mouse models [37] . Given these observations, we were curious to define the link between Cdc48/VCP function and accumulation of pathological protein aggregates in ALS, FTLD and IBMPFD, focusing on if Cdc48/VCP aids TDP-43 and FUS turnover, and if so by what mechanism.
Several studies have shown strong links between cytoplasmic TDP-43 and FUS protein localization, aggregation and neuron loss [15, 16] [38] . However, the mechanism of how cells clear these apparently toxic cytoplasmic aggregates is still unclear. In this report, we demonstrate that like TDP-43, cytoplasmic FUS expression impairs endocytosis rates in yeast. Interestingly, inhibition of Cdc48 and Ubx3 (a Cdc48 endocytosis-promoting co-factor) leads to defects in FUS and TDP-43 turnover and increased toxicity, while inhibition of VCP causes accumulation of TDP-43 and FUS protein and increases TDP-43 cytoplasmic aggregation. Additionally, Cdc48 physically interacts with and co-localizes with TDP-43 and endocytic proteins. Finally, TDP-43 cytoplasmic aggregates co-localize with VCP in ALS patient tissue. Taken together, these data suggest a role for Cdc48/VCP-facilitated endocytosis in regulating TDP-43 and FUS turnover and thus toxicity, which may represent a novel therapeutic target for numerous devastating neurodegenerative diseases characterized by TDP-43 and FUS cytoplasmic pathology.
Materials and methods

Yeast strains and growth conditions
Untransformed yeast strains were cultured at 30°C with YPD medium. Strains transformed with plasmids were grown in SD medium with appropriate nutrients for plasmid selection. In liquid culture, strains expressing GAL1-driven TDP-43 and FUS from plasmids (or vector controls) were initially cultured overnight in either 2% sucrose (if starter cultures were to be used for spotting assays) or 0.25% Galactose and 1.75% Sucrose (if starters were to be used for microscopy assays), then back diluted to OD600 0.1 in identical media, followed by growth to mid-log (OD600 0.3-0.6). 0.25% Galactose, rather than 2%, ensures more modest expression and toxicity of TDP-43 [26] and FUS (not shown), which facilitates identification of enhancer mutants. Transformation was performed by a standard LiAc method. All strains and plasmids used in this study are listed in Table S1 .
Yeast serial dilution assays
Yeast transformed with TDP-43, FUS or empty vector plasmids were grown overnight as described above, back-diluted to an OD600 of 0.2, serially diluted as indicated in figure legends, and spotted onto identical agar media.
HEK293A and TDP-43-GFP lentiviral integrated cell culture
HEK293A cell culture and generation of TDP-43-GFP stable integrated lines has been previously described [26] . Briefly, HEK293A cells with lentiviral integrated TDP-43-GFP or TDP-43 made to express a 35kDa TDP-43 fragment ("TDP-35-GFP"; amino acids 90-414; a cytoplasmic aggregation-prone allele mimicking cleavage by caspases [39] ) were cultured at 37°C in DMEM medium (HyClone, SH30022.01) with 10% FBS (Gibco, 26140079), 50 U/ml penicillin and 50 μg/ml streptomycin (Gibco, 15140-122). DbEQ (Apexbio Technology, A862910), a VCP inhibitor, was added at a concentration of 10uM for 1 hour prior to live-cell Deltavision microscopy (see below).
Fluorescence Microscopy
The methods have been described in detail previously [32] . Briefly, early stationary phase (OD600 >3.0) or mid-log cells (OD600 0.3-0.6) cells were examined using a DeltaVision Elite microscope. Data was analyzed by Fiji [40] . At least 50 cells (yeast or human) were analyzed per biological replicate, and all shown images are representative of a minimum of 3 biological replicates. % value indicates co-localization of TDP-43 or FUS with indicated proteins, which in yeast was scored in a blind manner with a minimum of 50 cells per biological replicate.
Western Blotting and protein stability assays
Western blotting was conducted as described previously [41] . Primary antibodies were as follows:
α-GFP (902602; Biolegend), α-TDP-43 (60019-2-Ig; ProteinTech), α-Vinculin (V4505; Sigma-Aldrich), α-Pgk1 (ab113687; Abcam), α-VCP (ab11433; Abcam), α-TAP (Thermofisher CAB1001) and α-GAPDH (MA5-15738, Invitrogen). For TDP-43 and FUS protein stability assays in yeast, expression was halted either by addition of cycloheximide at 0.2mg/ml (translational shut-off) or additional of 2% glucose to the growth media (transcriptional shut-off), as indicated in figure legends.
Endocytosis rate assays
Mid-log yeast cells (OD600 0.3-0.6) were harvested and incubated on ice for 10 minutes, then suspended in YPD containing 8μM FM4-64 (T3166, Thermo Fisher Scientific) at 25 o C and imaged at indicated time periods. HEK293A cells were kept on ice for 10 minutes, washed with live cell imaging solution (Thermo Fisher Scientific, A14291DJ) and then incubated with 25µg/ml fluorescent transferrin (T23362, Thermo Fisher Scientific) at 37°C for 15 minutes. Cells were then washed again with live cell imaging solution, imaged and quantified for intracellular fluorescence using Fiji.
Patient tissue immunofluorescence
Samples were dewaxed by xylene and fixed with successive incubations in 100%, 100%, 90%, 80%, 70% ethanol and distilled water for 10 minutes. Antigen was retrieved by keeping tissue slices in boiled sodium citrate buffer for 20 minutes. Endogenous peroxidases were quenched with 3% H2O2 for 30 minutes. Each slice was then blocked with 5% goat serum for 1 hour and then incubated with primary antibody overnight at 4°C. Following 4 TBS-T washes, each slice was incubated with an appropriate alexa fluor conjugated secondary antibody (Thermo Fisher Scientific). Slices were then washed 4 times in TBS-T, mounted with ProLong Gold Antifade DAPI mounting media (Molecular Probes, P36931) to stain the nuclei, and imaged.
Immunoprecipitation analyses
10 ml cultures of appropriately transformed yeast with suitable selective SD media were grown to mid-log growth phase (0.3-0.6 OD600), cell pellets harvested with 13000g centrifugation at 4 o C, and resuspended in 1ml of RIPA cell lysis buffer. 50% volume of glass beads (BioSpec Products, 11079105) were added, and cells vortexed for 20s before being incubated on ice; this was repeated twice more. Cells were centrifuged at 13,000g for 15mins to separate unylsed cells and insoluble cell debris. Supernatant was harvested, and protein concentration assessed for normalization via Bradford assay. Supernatants were incubated with magnetic dynabeads (Thermo fisher scientific) labelled with either αTAP antibody or αGFP antibody for 2 hours at 4C, followed by three bead washes in lysis buffer. Bound proteins were eluted with gel loading buffer, boiled in a standard SDS gel loading buffer at 95C for 5 minutes, and then subject to standard Western blot analyses.
Results
Cdc48 co-localizes with and mediates TDP-43 degradation and toxicity
VCP disease alleles are associated with cytoplasmic re-localization and aggregation of TDP-43 [32, 36, 37] , and mutant VCP toxicity in a fly model of ALS depends upon the cytoplasmic accumulation of TDP-43 [36] . However, mechanistic details of why VCP impairment affects cytoplasmic TDP-43 accumulation remain unclear. We began to address this using an established yeast TDP-43 model [18], focusing on interactions with the yeast VCP homolog Cdc48.
First, the localization of TDP-43 and Cdc48 was examined. Interestingly, expression of TDP-43 induced re-localization of Cdc48 from a predominantly nuclear region (mostly peri-nuclear in midlog cells) into cytoplasmic foci that exhibited approximately 60% co-localization with TDP-43 foci in mid-log and stationary phase conditions ( Fig. 1A) . Consistent with co-localization in foci, reciprocal immunoprecipitation of Cdc48-TAP and TDP-43-YFP revealed a robust interaction between Cdc48 and TDP-43 ( Fig. 1B-C) ; this is consistent with prior VCP-TDP-43 co-immunoprecipitation data from human cell culture and brain tissue [42] . In yeast, TDP-43 cytoplasmic foci co-localize with SGs, as has been previously shown [43] , and which we have also confirmed with various stress granule marker proteins (data not shown). Consistent with this, Cdc48-TAP immunoprecipitation also revealed a robust interaction with Pab1-GFP, a core SG component ( Fig. 1D ). Taken together, our data suggests that Cdc48 co-localizes with and physically interacts with TDP-43 and Pab1, likely at least partially within a SG context.
Next, we tested whether Cdc48 affected TDP-43 stability given the many roles Cdc48 plays in protein turnover. Since Cdc48 is an essential gene, we turned to a commonly used temperature sensitive (ts) mutant, cdc48-3, which possesses two missense point mutations, P257L and R387K that inhibit Cdc48's ATPase activity [44] . Protein degradation rate was measured by adding Cycloheximide (CHX) to block new protein synthesis. At the permissive temperature of 25°C, no change in TDP-43 turnover rate was examined in WT or cdc48-3 strains. However, at 35°C, which strongly impairs Cdc48-3 function, TDP-43 turnover rates were significantly decreased in the mutant strain relative to WT (Fig. 1E ). Finally, TDP-43 toxicity in yeast, evidenced by reduced cell growth in TDP-43 transformants relative to empty-vector control strains [10] , was exacerbated by inactivation of Cdc48 ( Fig. 1F ). Specifically, this was evident at temperatures that modestly (30°C) and strongly (35°C) inhibit Cdc48-3 function. Together, these data demonstrate that Cdc48 regulates TDP-43 protein stability and toxicity in yeast.
Cdc48 regulates TDP-43 toxicity in part by endocytosis
Cdc48 specificity of function is largely determined by use of co-factor proteins that help recruit it to its targets. In yeast, the Ubx family of proteins are a well described example of such proteins [45] .
Thus, we first examined TDP-43 toxicity in a range of Ubx null strains ( Fig. 2A) . Importantly, only deletion of UBX3, which functions along with Cdc48 in yeast endocytosis [46] , clearly exhibited enhanced TDP-43 toxicity ( Fig. 2A) . No clear effect with any other Ubx mutants on TDP-43 toxicity was observed, including UBX1 (SHP1) or UBX2 deletion, which facilitate Cdc48 function in autophagy and proteasomal turnover [47, 48] , ( Fig. 2A ). These findings are consistent with our prior work that endocytosis plays a greater role than autophagy in regulating TDP-43 toxicity and turnover in yeast during normal growth [26] . Finally, like Cdc48, Ubx3 foci localized with TDP-43 foci at a frequency of 53% ( Fig. 2B ).
We also examined additional gene deletion strains whose genes are either known Cdc48 co-factors, or have been linked to Cdc48 function [49] (Fig 2C) . Notably, deletion of UBP3 and BRE5 suppressed TDP-43 toxicity. Ubp3 is a deubiquitinase whose activity depends on co-factor Bre5, which also harbors an RNA binding domain. Deubiqutinases play many roles in Ubiquitin metabolism and are generally thought to stabilize proteins by antagonizing Ubiquitin-mediated turnover [50] .
Finally, we examined if Cdc48 exhibited any co-localization with endocytic proteins. We focused on subunits in the yeast phosphoinositide 3-kinase (PI3K) complex, namely Vps34 (PI3K itself) and
Vps38 (endocytosis-specific PI3K subunit), which aid endocytosis by generating phosphatidylinositol 3-phosphate (PI(3)P) for formation and maturation of early endosomes [51] .
We previously showed that both proteins co-localize strongly with cytoplasmic TDP-43-YFP foci in yeast cells [26] . In cells expressing untagged TDP-43, Cdc48 also co-localized well in distinct cytoplasmic foci with Vps34 and Vps38, [51] (Fig. 2D ). Together, these findings and the Ubx3 data suggest that Cdc48 regulation of TDP-43 involves endocytic function.
FUS toxicity and turnover depend on endocytic function and Cdc48
FUS shares many properties in common with TDP-43, including a propensity to form aggregates in ALS and other neurodegenerative diseases including FTLD [2] . A physical interaction between FUS and VCP has also been described [52] . A genetic link between knockdown of Cabeza (FUS ortholog) in Drosophila, and altered ter94 expression (VCP ortholog) has also been reported [53] .
However, evidence that toxicity of FUS (when expressed at physiological or high levels) or its turnover is regulated by VCP, or indeed by endocytosis in general has not been described. To determine if our findings with TDP-43 [26] were more generalizable to other aggregation prone disease-associated proteins, particularly those linked to ALS, we thus determined if FUS toxicity and turnover could be regulated by endocytosis and Cdc48 as well.
Several findings suggest that FUS, like TDP-43, is regulated by endocytic function in yeast. First, deletion of VPS15, VPS34 or VPS38, which impairs endocytosis, enhanced FUS toxicity (Fig. 3A) , similar to our prior work with TDP-43 [26] . Additionally, deletion of several other genes that facilitate maturation of endocytic compartments, including VPS8 (CORVET complex), VPS18
(CORVET/HOPS complex) and VPS21 (Rab5 protein) [54] also exacerbated FUS toxicity in yeast ( Fig S1A) . In contrast, deletion of core (ATG1, ATG8) and selective (ATG11) autophagy genes had no effect on FUS toxicity ( Fig S1B) . Second, deletion of VPS38, the PI3K endocytosis-specific subunit, induced FUS accumulation, which can be suppressed by Vps38 re-expression via plasmid ( Fig. 3B ). Third, FUS foci formation also increased in vps34Δ and vps38Δ null strains, while showing no increase over WT in atg8Δ strains ( Fig 3C) . Fourth, overexpression of VPS34 and VPS38 rescued FUS induced cell toxicity (Fig. 3D ). This partly mirrors our prior observation that Vps38 over-expression rescues TDP-43 induced cell toxicity, which correlates with increased endocytic activity [26] . Finally, FUS protein stability showed no stabilization in an atg1Δ strain background, but significantly stronger stabilization in a vps9Δ (Rab5 GEF), and vps34Δ background ( Fig 3E) . Interestingly, FUS protein levels were particularly elevated in vps34Δ cells versus WT (mirroring Fig 3B) , with a modest increase in both vps9Δ and atg1Δ strains ( Fig S1C) . Taken together, this suggests that in yeast, endocytic function is a key regulator of FUS toxicity and turnover, while autophagy may play a small role in turnover.
In our prior work [26] , any endocytosis-related mutant that increased TDP-43 steady state protein levels and/or increased TDP-43 stability, also increased TDP-43 toxicity. Higher transcriptionallydriven expression of TDP-43 also increased toxicity in yeast [26] . However, despite increased TDP-43 protein stability in vacuolar protease mutants [26] , TPD-43 toxicity in vacuolar protease mutants does not alter relative to WT cells ( Fig S1D) . We observe the same phenomenon for FUS ( Fig S1E) .
Thus, FUS and TDP-43 toxicity likely depends on cytoplasmic location and neither proteins are presumably toxic if accumulated within vacuoles.
Finally, we determined whether Cdc48 played a role in regulation of FUS and found similar results to those observed with TDP-43. First, partial and strong inhibition of Cdc48 at 30°C and 35°C respectively enhanced FUS toxicity in the cdc48-3 strain ( Fig S2A) . Second, inactivation of Cdc48 at 35°C also lead to a significant increase in FUS protein stability ( Fig S2B) Third, of all Ubx null strains examined, only deletion of UBX3, which functions in endocytosis [46] , clearly increased FUS toxicity ( Fig S2C) . Interestingly, as with TDP-43, bre5Δ and ubp3Δ strains also suppressed FUS toxicity ( Fig S2D) .
In summary, these data suggest that FUS toxicity and turnover, as with TDP-43, is likely regulated in part by a Cdc48-facilitated endocytic process.
Endocytosis rate is regulated by Cdc48, TDP-43 and FUS
TDP-43 expression in yeast and human cells impairs endocytosis rates, and TDP-43 toxicity and protein accumulation are suppressed by driving endocytosis rates by VPS38 (yeast) or RAB5 (human cell) over-expression [26] . Having made similar toxicity and protein level observations for FUS in yeast ( Fig. 3B and C) , we were curious if FUS, like TDP-43, also inhibited endocytosis. We were also curious if defects in endocytosis caused by Cdc48 inactivation using the cdc48-3 ts allele would be epistatic to, additive or synergistic with effects of TDP-43 or FUS expression.
Yeast endocytosis rates were measured by following uptake of an extracellular dye, FM4-64, which is endocytosed and ultimately stains vacuolar membranes. The faster and more intensely that vacuolar membrane staining occurs, the better endocytosis is functioning [55] . In WT cells, vacuole staining was clearly visible by 5 minutes, and intense by 10 minutes (Fig. 4A, D) . Like TDP-43 [26] , expression of FUS also impaired endocytosis rates, evident by reduced vacuolar staining over the same time period (Fig 4B-D) . Consistent with previous mammalian [31, 33] and yeast cell findings [46] , inactivation of Cdc48 also impaired endocytosis rates to a similar extent as FUS expression, though not quite as strikingly as TDP-43 expression ( Fig. 4A-D) . Combining TDP-43 or FUS expression with Cdc48 inactivation lead to a significant additive inhibitory effect on endocytosis ( Fig.   4B-D) . Taken together, this suggests that both FUS and TDP-43 inhibit endocytosis, in a manner at least partly independent of blocking Cdc48 function.
VCP regulates endocytosis and TDP-43/FUS turnover in mammalian cells
We next turned our focus to VCP in human cells. VCP is a known regulator of endocytosis, localizing to and affecting early endosome size [33] , and ultimately affects endocytosis trafficking rates and endocytic substrate turnover in lysosomes [31, 33] . First, we examined if VCP localized with Rab5, an early endosomal marker. HEK293A cells transfected with VCP-GFP and Rab5-mRFP constructs exhibited significant co-localization of both proteins ( Fig S3A) , consistent with prior work in COS7 lines expressing the constitutively active Rab5 Q79L mutant that drives earlyendosome enlargement [33] . Next, endocytic uptake of fluorescently-labelled transferrin [56] was performed to measure clathrin-dependent endocytosis rates in WT and VCP knock down cells.
Dynasore, a small-molecule inhibitor of dynamin, was used as a positive control of endocytic impairment [57] . As expected, VCP knock down cells exhibited impaired endocytosis, albeit to a lesser degree than in Dynasore-treated cells ( Fig S3B) ; this is consistent with similar data in COS7 cells using Eer1, a VCP inhibitor [33] . These data confirm that VCP positively regulates endocytic function in our cell line model. We next determined if TDP-43 and FUS steady state levels in HEK293A cells were affected when endocytosis was inhibited. Both dynasore treatment and knock down of VCP increased steady state TDP-43 and FUS levels, mirroring findings in yeast (Fig. 5A ). Using TDP-43-GFP lentiviral integrated HEK293A lines [26] , we also examined whether VCP inactivation using the specific Finally, using immunofluoresence, we examined VCP co-localization with TDP-43 aggregates in frontal cortex tissue from ALS disease and control patients. This revealed that VCP is significantly localized with TDP-43 aggregates in ALS tissue samples, relative to control patients (Fig. 5D, 5E ), again mirroring Cdc48 co-localization with TDP-43 in yeast.
In summary, our data suggests that the previously reported genetic interactions between VCP and TDP-43 [36] , and re-localization of TDP-43 to cytoplasmic foci in VCP mutant contexts [32, 36, 37] , may reflect a role for VCP in facilitating cytoplasmic TDP-43 turnover, at least in part via an endocytic mechanism. Our yeast data suggests that Cdc48/VCP may also act similarly on cytoplasmic FUS. These findings are relevant to therapeutic development not only for ALS, but other TDP-43/FUS proteinopathies, including FTLD and particularly IBMPFD, where VCP mutations account for most disease cases.
Discussion
Several pieces of evidence suggest that Cdc48 and VCP's effect on TDP-43 and FUS toxicity and turnover may depend on an endocytosis-promoting function. First, inactivation of Cdc48 [46] , VCP [33] , or expression of either FUS or TDP-43 impair endocytosis ( Fig. 4-5 ). Second, combining expression of either of these aggregation prone proteins with Cdc48-3 inactivation further exacerbates endocytosis inhibition ( Fig. 4) and TDP-43/FUS toxicity (Fig. 1F, 3D ). Third, TDP-43 and FUS toxicity is increased in ubx3Δ strains ( Fig. 2A, Fig S2B) , which promotes endocytosis [38] .
In contrast, deletion of all other Ubx Cdc48 co-factors, including Ubx1 and Ubx2, which function in autophagic and proteasomal turnover pathways [47, 48] , had no effect on TDP-43 or FUS toxicity.
Interestingly, Ubx3 also forms part of a membrane associated E3 ubiquitin ligase complex found throughout the endocytic pathway, but particularly at vacuolar membranes, where it is implicated in ESCRT-dependent turnover of vacuolar membrane transporter proteins in the vacuole itself [51] .
Fourth, TDP-43 and FUS shows no increase in cellular toxicity in yeast when autophagy is blocked, but do when endocytosis is inhibited [26] (Fig. 3A, Fig. S1A-B) . Fifth, Cdc48 and VCP show strong co-localization with endocytic proteins (Fig. 2D, Fig S3A) . Finally, mutations in VCP associated with disease can specifically affect interactions with the endocytosis-promoting cofactor UBXD1 [31] , though notably defects in autophagy have also been reported for such mutants [60] . However, this may also reflect defects in endocytosis given the interconnected nature of endocytic and autophagic pathways in human cells [61] . Taken together, these data argue that at least part of the mechanism by which Cdc48 and VCP mediate TDP-43 and FUS protein levels, and their toxicity, is by facilitating turnover by a mechanism dependent on endocytosis activity. VCP and Cdc48 have been linked to several distinct aspects of endocytic function [31, 33] . For example, VCP interacts with and decreases the formation of EEA1 oligomers (early endosomeassociated antigen 1). EEA1 promotes fusion of endocytic vesicles into early endosomes, thus increased EEA1 oligomerization may explain an increase in early endosome size that accompanies VCP knockdown or chemical inhibition [33] . VCP inhibition and disease mutations also impair endolysosomal sorting and/or eventual turnover of membrane associated proteins such as epidermal growth factor receptor (EGFR) and Caveolar-1 (CAV-1), which itself functions in caveolar-mediated endocytosis [31] [62] . A role for a VCP co-factor, UBXD1, in CAV-1 endolysomal sorting and turnover was also identified [31] . VCP also robustly interacts with clathrin in human cells [63] , while in yeast, the Cdc48 cofactor Ubx3 interacts with clathrin and functions in clathrinmediated endocytosis, as does Cdc48 [46] .
We propose that TDP-43 and FUS can be degraded in lysosomes/vacuoles by an endocytosisdependent trafficking mechanism stimulated by Cdc48/VCP function. A key question is how might Cdc48 and VCP promote TDP-43 and FUS turnover via endocytosis? We propose two general models (Fig 6) , which are not mutually exclusive. First, as described above and reviewed elsewhere [28, 30] , Cdc48/VCP may drive various steps in the endocytic pathway. If TDP-43 and FUS can enter endocytic compartments independently of a physical interaction with Cdc48/VCP, en route to clearance in vacuoles/lysosomes, then Cdc48/VCP impairment and resulting endocytic downregulation may indirectly result in TDP-43 and FUS accumulation.
Alternatively, a second possibility is that Cdc48/VCP may directly interact with TDP-43 and FUS aggregates and promote a remodeling event (e.g. aggregate disruption, targeting to endocytic vesicles) that facilitates TDP-43 and FUS trafficking via the endocytic pathway, resulting in their turnover in lysomes/vacuoles. Supporting this, Cdc48 physically interacts with TDP-43 (Fig. 1B) , and co-localizes, as does Ubx3, with TDP-43 aggregates (Fig. 1A; Fig. 2B ). However, whether these aggregates are active sites of TDP-43 clearance activity or may form part of the mechanism by which TDP-43 impairs endocytosis activity, possibly by sequestration of endocytic factors including Cdc48, remains unclear. Interestingly, TDP-43 and FUS cytoplasmic aggregates are typically ubiquitinated [64, 65] , thus making them likely substrates for Cdc48/VCP activity. In addition, Cdc48/VCP cofactors may even facilitate TDP-43 or FUS ubiquitination events themselves, given the role of Ubx3 in an E3 ubiquitin ligase complex described previously, and the fact that multiple VCP cofactors interact with E3 ubiquitin ligases [66] .
Cdc48/VCP could also promote disassembly and turnover of TDP-43/FUS aggregates by the proteasome or autophagy. However, our prior TDP-43 data in yeast [26] , and similar work by the Braun lab [27] argues against a significant role for the proteasome or autophagy in clearing TDP-43 in yeast under normal growth conditions. Similarly, for FUS, no significant impact of impairing autophagy on FUS toxicity was observed ( Fig. S1B) , though a minor role in turnover was seen ( Fig   S1C) . A key area of future research will be to determine in great mechanistic detail how VCP promotes TDP-43 and FUS turnover in an endocytic-dependent manner.
An intriguing result was the observation that Ubp3 and Bre5 null yeast suppressed TDP-43 and FUS toxicity. The Ubp3/Bre5 complex has been identified as a regulator of numerous vesicular trafficking pathways, including as a negative regulator of mitophagy [67] , and a positive effector of ribophagy [68] , the cytoplasm to vacuole trafficking pathway [69] , and ER-Golgi transport [70] . In yeast, Ubp3 and Bre5 also localize within stress granules [71] , and facilitate assembly of stationary phased induced stress granules [72] ; indeed Ubp3 and Bre5 are homologs of USP10 and G3BP1, which are also key regulators of mammalian stress granule assembly [73, 74] . Thus, a formal possibility (the subject of another work in preparation), is that impaired stress granule assembly may limit TDP-43 aggregation, accumulation and toxicity. Alternatively, loss of Bre5 and Ubp3 function may also reflect altered regulation of various autophagic trafficking pathways or increased turnover of proteins by the proteasome.
Defects in endocytosis have been associated with various neurodegenerative diseases including
Alzheimer's disease and Parkinson's disease [75] [76] [77] [78] . Furthermore, aggregation prone neurodegenerative disease protein clearance via endocytic-dependent means has also been previously suggested. Specifically, α-synuclein degradation in human cell models occurs at least partly by the endolysomal pathway, independent of autophagy and proteasomal turnover [79] , while late defects in endocytic trafficking lead to accumulation of polyQ Huntingtin aggregates in yeast Huntingtin models [80] . Several genes associated with ALS onset, including ALS2, FIG4 and CHMP2B also function in endocytosis (discussed in [26] ). Additionally, C9ORF72, the most commonly mutated gene identified in ALS, also shares DENN domain similarly with Rab GEF proteins, and exhibits co-localization with Rab5. In addition, depletion of C9ORF72 inhibits endocytosis rates in neuroblastoma cells [81] , accelerates degeneration of induced motor-neurons (iMNs) derived from ALS patients, and correlates with endocytic trafficking defects [82] . Strikingly, genetic and pharmacological interventions that enhanced endocytic trafficking in the iMN model, and C9ORF72 mouse models, also suppressed ALS-associated degeneration phenotypes [82] .
Thus, we speculate that endocytic dysfunction may promote accumulation of cytoplasmic TDP-43 and FUS, leading to aggregation. This may be a key part of the pathology of ALS and related degenerative diseases characterized by TDP-43 and/or FUS inclusion bodies, and thus an attractive target for therapeutic development. (B) Growth assays in indicated strains expressing empty vector or FUS plasmids. (C) WT and cdc48-3 strains were treated with 0.2 mg/ml Cycloheximide (CHX) for the indicated time at either 25°C or 35°C. FUS protein stability was quantified following normalization to a PGK1 loading control.
(D) Serial dilution growth assay with GAL1-regulated FUS plasmid in indicated strains.
